Advances in psychiatry and nuerology


ISSN 1234-8279

ISSN on-line 2449-9315 

 

As of July 2026, the journal's publisher is Wroclaw Medical University: https://ppn.umw.edu.pl/en/about/.

 

CiteScore 2025: 0.4

MNiSW: 20

Index Copernicus 2023: 90.54

Editorial panel
Submitting and reviewing works online

Archive 1995–2023

2018, volume 34, issue 4
Review article

Adverse effects of venlafaxine therapy and risk factors for their occurrence

Justyna Suwała1, Marta Oleś1, Anna Wiela-Hojeńska1
1. Katedra i Zakład Farmakologii Klinicznej, Uniwersytet Medyczny im. Piastów Śląskich we Wrocławiu
Farmakoterapia w Psychiatrii i Neurologii 2018, 34 (4), 285–304
Date of publication: 2019-01-08
Keywords: venlafaxine, adverse effects, risk factors
Summary

Pharmacovigilance is an important aspect of depression treatment, considering that 40–90% of patients experience side effects of antidepressant use. This paper discusses the issues of optimising the use of venlafaxine, including its pharmacodynamic and pharmacokinetic properties, indications, adverse effects and risk factors for their occurrence, such as co-morbidities or genetic polymorphisms and interactions with other drugs.

Correspondence address
mgr farm. Justyna Suwała
Uniwersytet Medyczny
im. Piastów Śląskich we Wrocławiu
email: justyna.suwala@student.umed.wroc.pl
You have added an item to your cart
Restore password
Shopping cart (0)
No products in your cart
Font size
Contrast
Underlined links